OKYO Pharma (NASDAQ:OKYO – Get Rating) and Seagen (NASDAQ:SGEN – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Earnings and Valuation

This table compares OKYO Pharma and Seagen's revenue, earnings per share and valuation.

OKYO Pharma has higher earnings, but lower revenue than Seagen.

Profitability

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for OKYO Pharma and Seagen, as reported by MarketBeat.com.

Seagen has a consensus price target of $160.67, indicating a potential upside of 26.49%. Given Seagen's higher possible upside, analysts plainly believe Seagen is more favorable than OKYO Pharma.

Institutional and Insider Ownership

0.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 86.3% of Seagen shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by insiders. Comparatively, 27.3% of Seagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

OKYO Pharma beats Seagen on 5 of the 9 factors compared between the two stocks.

About OKYO Pharma

(Get Rating)

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

About Seagen

(Get Rating)

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.